Establishment Labs (NASDAQ:ESTA) Rating Lowered to “Hold” at Wall Street Zen

Establishment Labs (NASDAQ:ESTA) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

Other analysts also recently issued research reports about the stock. Needham & Company LLC raised their price target on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Tuesday, February 24th. BTIG Research increased their price objective on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a research note on Tuesday, February 24th. Canaccord Genuity Group raised their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Stephens boosted their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Citigroup cut their target price on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.86.

Establishment Labs Stock Performance

NASDAQ:ESTA opened at $55.31 on Friday. The stock has a market cap of $1.62 billion, a price-to-earnings ratio of -31.79 and a beta of 0.91. Establishment Labs has a one year low of $26.56 and a one year high of $83.31. The company has a debt-to-equity ratio of 10.51, a quick ratio of 2.00 and a current ratio of 3.04. The business’s 50-day simple moving average is $68.98 and its 200 day simple moving average is $62.21.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The firm had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same quarter last year, the firm earned ($1.19) EPS. Establishment Labs’s quarterly revenue was up 45.2% on a year-over-year basis. As a group, sell-side analysts predict that Establishment Labs will post -2.41 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Quiros Juan Jose Chacon sold 3,575 shares of the firm’s stock in a transaction on Wednesday, March 25th. The stock was sold at an average price of $60.08, for a total transaction of $214,786.00. Following the transaction, the director directly owned 1,220,004 shares in the company, valued at $73,297,840.32. This trade represents a 0.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 11.44% of the company’s stock.

Institutional Trading of Establishment Labs

Institutional investors have recently added to or reduced their stakes in the business. Simplify Asset Management Inc. acquired a new position in shares of Establishment Labs in the 3rd quarter valued at about $1,555,000. Tejara Capital Ltd raised its stake in Establishment Labs by 31.2% during the third quarter. Tejara Capital Ltd now owns 102,494 shares of the company’s stock worth $4,201,000 after acquiring an additional 24,386 shares during the period. Woodson Capital Management LP lifted its holdings in Establishment Labs by 113.3% in the third quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after acquiring an additional 255,000 shares during the last quarter. Hood River Capital Management LLC lifted its holdings in Establishment Labs by 138.2% in the second quarter. Hood River Capital Management LLC now owns 53,124 shares of the company’s stock worth $2,269,000 after acquiring an additional 30,825 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its stake in Establishment Labs by 19.6% in the second quarter. Affinity Asset Advisors LLC now owns 334,863 shares of the company’s stock valued at $14,302,000 after acquiring an additional 54,863 shares during the period. Institutional investors own 72.91% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.